Start Of Phase IIb Clinical Study With CYT003-QbG10 Monotherapy For The Treatment Of Allergic Diseases
14 Feb 2008
Cytos Biotechnology Ltd (SIX:CYTN) announced
today that it has started a phase IIb clinical study with CYT003-QbG10, an allergen-independent
immunotherapeutic product candidate for the treatment of allergy and asthma. The study is a
randomized, double-blind, placebo-controlled, multicenter dose-finding study to evaluate the safety,
tolerability and efficacy of two different doses of CYT003-QbG10. It will include 300 patients with
rhinoconjunctivitis Read the rest of this entry »